Bellai-Dussault Kara, Dougan Shelley D, Fell Deshayne B, Lavin Venegas Carolina, Little Julian, Meng Lynn, Okun Nan, Walker Mark, Armour Christine M, Potter Beth K
University of Ottawa, School of Epidemiology and Public Health, Ottawa, Ontario, Canada.
Prenatal Screening Ontario, Better Outcomes Registry & Network (BORN) Ontario, Ottawa, Ontario, Canada.
Acta Obstet Gynecol Scand. 2024 Dec;103(12):2499-2510. doi: 10.1111/aogs.14965. Epub 2024 Sep 29.
Nuchal translucency prenatal ultrasound is widely used to screen for chromosomal abnormalities. An elevated nuchal translucency has been associated with adverse outcomes such as pregnancy loss; however, extant studies investigating these associations have had important limitations, including selection bias. This study aimed to investigate the association between nuchal translucency measurements and pregnancy outcome, specifically, a composite of pregnancy loss, termination, stillbirth, or neonatal death.
This was a population-based retrospective cohort study conducted with data from the prescribed perinatal registry in Ontario, Canada, Better Outcomes Registry & Network. All singleton pregnancies with an estimated date of delivery from September 1, 2016, to March 31, 2021, and multiple marker screening including a nuchal translucency were included. Pregnancies with measurements 2.0- < 2.5 mm, 2.5- < 3.0 mm, 3.0- < 3.5 mm, 3.5- < 5.0 mm, 5.0- < 6.5 mm, and ≥6.5 mm were compared to a reference group with measurements <2.0 mm. We used multivariable modified Poisson regression models with robust variance estimation to estimate associations between nuchal translucency measurement and pregnancy outcome, with adjustment for age at estimated date of delivery and gestational age at screening.
There were 414 268 singleton pregnancies included in the study. The risk of pregnancy loss, termination, stillbirth, or neonatal death increased with increasing levels of nuchal translucency measurements, with an adjusted risk ratio (aRR) of 11.9 (95% confidence interval (CI) 9.9, 14.3) in the group with measurements 3.5- < 5.0 mm. When pregnancies with diagnosed chromosomal abnormalities were excluded, this association remained strong, with an aRR of 6.4 (95% CI 4.8, 8.5). Among pregnancies with a live birth, those with a higher nuchal translucency measurement (>5.0 mm vs. <2.0 mm) were also at increased risk of adverse perinatal outcomes such as admission to the neonatal intensive care unit and APGAR score <7.
In this population-based study using robust methods to reduce the risk of selection bias, we found that pregnancies with increased nuchal translucency measurements are less likely to result in a live birth, even with the exclusion of chromosomal abnormalities. Pregnancies with increased nuchal translucency measurements that resulted in a live birth may also be at increased risk of adverse perinatal outcomes.
颈部半透明产前超声检查被广泛用于筛查染色体异常。颈部半透明增厚与诸如流产等不良结局相关;然而,现有的调查这些关联的研究存在重要局限性,包括选择偏倚。本研究旨在调查颈部半透明测量值与妊娠结局之间的关联,具体而言,是流产、终止妊娠、死产或新生儿死亡的综合情况。
这是一项基于人群的回顾性队列研究,使用了加拿大安大略省规定的围产期登记处“更好结局登记与网络”的数据。纳入了所有预计分娩日期在2016年9月1日至2021年3月31日之间的单胎妊娠,以及包括颈部半透明测量在内的多项标志物筛查。将测量值为2.0 - <2.5毫米、2.5 - <3.0毫米、3.0 - <3.5毫米、3.5 - <5.0毫米、5.0 - <6.5毫米和≥6.5毫米的妊娠与测量值<2.0毫米的参照组进行比较。我们使用具有稳健方差估计的多变量修正泊松回归模型来估计颈部半透明测量值与妊娠结局之间的关联,并对预计分娩日期时的年龄和筛查时的孕周进行了调整。
该研究纳入了414268例单胎妊娠。随着颈部半透明测量值水平的升高,流产、终止妊娠、死产或新生儿死亡的风险增加,测量值为3.5 - <5.0毫米组的调整风险比(aRR)为11.9(95%置信区间(CI)9.9,14.3)。当排除诊断为染色体异常的妊娠时,这种关联仍然很强,aRR为6.4(95%CI 4.8,8.5)。在活产妊娠中,颈部半透明测量值较高(>5.0毫米对比<2.0毫米)的妊娠发生不良围产期结局的风险也增加,如入住新生儿重症监护病房和阿氏评分<7。
在这项基于人群的研究中,我们采用了稳健的方法来降低选择偏倚的风险,发现即使排除染色体异常,颈部半透明测量值增加的妊娠活产的可能性较小。颈部半透明测量值增加且活产的妊娠发生不良围产期结局的风险也可能增加。